Cardiome Pharma Corporation (NASDAQ:CRME) reported 6/30/2017 earnings this Afternoon, coming in at ($0.26) per share, missing Wall Street’s estimates of ($0.17) per Share. Revenue for the quarter came in at $5.75 million missing the streets estimates of $6.88 million
Analyst Coverage For Cardiome Pharma Corporation (NASDAQ:CRME)
These are 1 Hold Rating, 5 Buy Ratings .
The current consensus rating for Cardiome Pharma Corporation (NASDAQ:CRME) is Buy (Score: 2.83) with a consensus target price of $6.65 , a potential (61.80% upside)
Recent Trading for Cardiome Pharma Corporation (NASDAQ:CRME) Shares of Cardiome Pharma Corporation closed the previous trading session at 4.11 down -0.08 -1.91% with 36,768 shares trading hands.